MicroRNA调控胃癌多药耐药的研究进展  

Advances on microRNA regulating multidrug resistance of gastric cancer

作　　者：蔡颖[1] 徐玲[1] 张晔[1] 

机构地区：[1]中国医科大学第一临床学院,辽宁沈阳110001

出　　处：《现代肿瘤医学》2017年第14期2334-2336,共3页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81270036);辽宁省自然科学基金(编号:2014021069);辽宁省教育厅优秀人才项目(编号:LR2014023)

摘　　要：晚期胃癌最常用的治疗方法是化疗,但患者存在对化疗药物原发或继发的多药耐药(multidrug resistance,MDR)现象,使患者很难获得长期生存。大量研究证实,microRNA是转录后基因表达调节的关键分子,在肿瘤的多种生物学行为中起着关键性作用,本文就microRNA调控胃癌多药耐药的相关研究进展做一综述。Chemotherapy is the most effective treatment of advanced gastric cancer. But it is difficult to obtain long - term survival with the multidrug resistance to chemotherapy primary or secondary multidrug resistance（ MDR） reason. Therefore, gastric cancer multidrug resistance related research has become a hot spot. In recent years, studies have confirmed that microRNA as post - transcriptional regulator plays a key role in a variety of biological behavior of tumor, involved in gastric carcinogenesis and development process. This paper reviews research progress about microR-NA regulating multidrug resistance of gastric cancer.

关 键 词：胃癌 MDR 微小RNA 

分 类 号：R730.1[医药卫生—肿瘤]